Not everyone diagnosed with cancer is a candidate for pembrolizumab. Eligibility depends on a combination of factors that an oncologist assesses through your medical history, test results, and clinical situation. Understanding those factors helps you have a more informed conversation with your clinical team.
Cancer type
Pembrolizumab has regulatory approval for a specific list of cancer types. Current approvals in the UK and Europe include:
- Non-small cell lung cancer (NSCLC)
- Melanoma (advanced and adjuvant)
- Head and neck squamous cell carcinoma (HNSCC)
- Urothelial carcinoma (bladder cancer)
- Cervical cancer
- Endometrial carcinoma
- Oesophageal and gastro-oesophageal junction cancer
- Biliary tract cancer (in combination)
- Colorectal cancer with MSI-H or dMMR status
- Triple-negative breast cancer (in combination, locally advanced or metastatic)
Approvals continue to expand as new trial data emerges. If your cancer type is not on the current approved list, pembrolizumab would only be available within a clinical trial setting.
PD-L1 expression
Most pembrolizumab approvals require a minimum level of PD-L1 expression in the tumour. This is measured from a tissue sample using immunohistochemistry and reported as a Tumour Proportion Score (TPS) or Combined Positive Score (CPS), depending on cancer type. The required threshold varies: in NSCLC, a TPS of 50% or higher qualifies for monotherapy; lower scores may still qualify for combination approaches. Some indications - such as MSI-H tumours - do not require PD-L1 positivity at all.
Performance status and general health
Performance status is a standardised measure of how well you are able to carry out daily activities. The ECOG scale (0-4) is most commonly used. Most pembrolizumab trials enrolled patients with ECOG 0 (fully active) or 1 (restricted in strenuous activity only). Patients with ECOG 2 may still be eligible in some settings, but the evidence base is less robust. Patients requiring assistance with self-care (ECOG 3-4) are generally not considered for pembrolizumab outside carefully considered clinical decisions.
Active autoimmune disease requiring systemic treatment is a relative contraindication, as pembrolizumab can exacerbate autoimmune conditions. Patients on high-dose corticosteroids, those with prior solid organ transplants, or those with certain other immune-related conditions require careful individual assessment.
Prior treatment history
Whether pembrolizumab is used as a first treatment (first-line) or after prior therapy (second-line or beyond) depends on the specific cancer and the approved indication. For NSCLC with high PD-L1 expression, pembrolizumab is typically offered as the first treatment. For others, it follows a platinum-based chemotherapy course. Your oncologist will advise on the appropriate treatment sequence for your situation.
If you have previously received anti-PD-1 or anti-PD-L1 therapy, re-treatment with pembrolizumab is generally not considered, as cross-resistance makes further benefit unlikely.
Not sure if you qualify? Start here.
Our three-minute eligibility check covers your cancer type, PD-L1 score, and medical history. An oncologist reviews every submission within 24 hours and provides a clear response.
Check your eligibility